Pembrolizumab (Keytruda, Merck Sharp & Dohme) has a marketing authorisation as monotherapy 'for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV'.
Pembrolizumab (200 mg) is given every 3 weeks by intravenous infusion, until disease progression or unacceptable toxicity.
£2,630 per 100‑mg vial (excluding VAT; company submission). The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.